Total Payments
$294,244
2024 Payments
$73.08
Companies
8
Transactions
262
Medicare Patients
17,013
Medicare Billing
$14.4M
Payment Breakdown by Category
Other$213,801 (72.7%)
Consulting$40,408 (13.7%)
Travel$33,154 (11.3%)
Food & Beverage$5,250 (1.8%)
Research$1,632 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $208,276 | 57 | 70.8% |
| Consulting Fee | $40,408 | 14 | 13.7% |
| Travel and Lodging | $33,154 | 87 | 11.3% |
| Current or prospective ownership or investment interest | $5,525 | 7 | 1.9% |
| Food and Beverage | $5,250 | 88 | 1.8% |
| Unspecified | $1,632 | 9 | 0.6% |
Payments by Type
General
$292,612
253 transactions
Research
$1,632
1 transactions
Ownership
$0
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $192,199 | 136 | $0 (2024) |
| Allergan, Inc. | $94,555 | 100 | $0 (2021) |
| US Retina LLC | $5,525 | 15 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $1,632 | 1 | $0 (2023) |
| Genentech USA, Inc. | $230.43 | 5 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $35.46 | 2 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $34.90 | 2 | $0 (2020) |
| Apellis Pharmaceuticals, Inc. | $31.85 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $73.08 | 4 | Regeneron Healthcare Solutions, Inc. ($28.97) |
| 2023 | $1,760 | 7 | Regeneron Pharmaceuticals, Inc. ($1,632) |
| 2022 | $5,614 | 7 | Regeneron Healthcare Solutions, Inc. ($3,119) |
| 2021 | $6,306 | 10 | Regeneron Healthcare Solutions, Inc. ($2,788) |
| 2020 | $24,119 | 22 | Regeneron Healthcare Solutions, Inc. ($19,543) |
| 2019 | $70,698 | 55 | Regeneron Healthcare Solutions, Inc. ($53,124) |
| 2018 | $65,156 | 59 | Regeneron Healthcare Solutions, Inc. ($42,273) |
| 2017 | $120,518 | 98 | Regeneron Healthcare Solutions, Inc. ($71,267) |
All Payment Transactions
262 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/01/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $28.97 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/24/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $24.77 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/09/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: Ophthalmology | ||||||
| 2024 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 10/17/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $36.09 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/10/2023 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $16.12 | General |
| Category: Ophthalmology | ||||||
| 06/13/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $23.55 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/21/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | — | In-kind items and services | $1,631.82 | Research |
| Study: A RANDOMIZED, SINGLE-MASKED, ACTIVE-CONTROLLED PHASE 2 STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF REPEATED DOSES OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION • Category: OPHTHALMOLOGY | ||||||
| 04/11/2023 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $31.85 | General |
| Category: Ophthalmology | ||||||
| 02/08/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: OPHTHALMOLOGY | ||||||
| 2023 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 09/20/2022 | Genentech USA, Inc. | VABYSMO (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 08/04/2022 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,733.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/13/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $2,025.75 | General |
| 04/12/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $304.00 | General |
| 04/12/2022 | Genentech USA, Inc. | SUSVIMO (Drug), VABYSMO | Food and Beverage | In-kind items and services | $15.55 | General |
| Category: Immunology and Ophthalmology | ||||||
| 02/15/2022 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,386.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 2022 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 12/08/2021 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $15.75 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/10/2021 | Allergan, Inc. | OZURDEX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: RETINA | ||||||
| 10/07/2021 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,386.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/13/2021 | Allergan, Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: RETINA | ||||||
| 05/11/2021 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $1,044.15 | General |
| 05/06/2021 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $158.37 | General |
| 04/13/2021 | Allergan, Inc. | OZURDEX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: RETINA | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, SINGLE-MASKED, ACTIVE-CONTROLLED PHASE 2 STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF REPEATED DOSES OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | Regeneron Pharmaceuticals, Inc. | $1,632 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 4,448 | 82,875 | $8.0M | $4.2M |
| 2022 | 22 | 4,497 | 17,561 | $7.3M | $3.5M |
| 2021 | 17 | 4,287 | 14,896 | $7.6M | $3.6M |
| 2020 | 14 | 3,781 | 13,062 | $6.5M | $3.1M |
Total Patients
17,013
Total Services
128,394
Medicare Billing
$14.4M
Procedure Codes
70
All Medicare Procedures & Services
70 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 333 | 71,160 | $3.0M | $2.1M | 69.3% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 310 | 1,642 | $2.1M | $1.1M | 55.1% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 1,234 | 2,880 | $576,000 | $262,237 | 45.5% |
| J3490 | Unclassified drugs | Office | 2023 | 45 | 109 | $339,400 | $197,280 | 58.1% |
| 67028 | Injection of drug into eye | Office | 2023 | 479 | 2,166 | $1.1M | $194,988 | 17.1% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 37 | 1,085 | $217,000 | $130,591 | 60.2% |
| 92134 | Imaging of retina | Office | 2023 | 1,265 | 3,048 | $426,720 | $91,700 | 21.5% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 345 | 345 | $86,250 | $37,082 | 43.0% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 17 | 17 | $42,500 | $15,774 | 37.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 77 | 77 | $19,250 | $9,862 | 51.2% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 12 | 14 | $35,000 | $9,477 | 27.1% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 52 | 63 | $12,600 | $6,436 | 51.1% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 67 | 83 | $12,450 | $5,955 | 47.8% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 20 | 22 | $36,300 | $4,292 | 11.8% |
| 92250 | Photography of the retina | Office | 2023 | 123 | 127 | $25,400 | $3,533 | 13.9% |
| 92002 | New patient problem focused exam of visual system | Office | 2023 | 15 | 15 | $2,250 | $908.09 | 40.4% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 17 | 22 | $6,600 | $790.84 | 12.0% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 389 | 3,409 | $4.3M | $2.4M | 57.3% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 1,149 | 2,869 | $573,800 | $266,044 | 46.4% |
| 67028 | Injection of drug into eye | Office | 2022 | 429 | 2,112 | $1.1M | $189,383 | 17.9% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 36 | 4,200 | $175,014 | $125,334 | 71.6% |
| J3590 | Unclassified biologics | Office | 2022 | 40 | 70 | $175,000 | $123,793 | 70.7% |
| 92134 | Imaging of retina | Office | 2022 | 1,151 | 3,012 | $421,680 | $93,195 | 22.1% |
| J3490 | Unclassified drugs | Office | 2022 | 21 | 35 | $87,500 | $62,149 | 71.0% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 12 | 168 | $84,000 | $39,031 | 46.5% |
About Dr. Adam Gerstenblith, MD
Dr. Adam Gerstenblith, MD is a Internal Medicine healthcare provider based in Hagerstown, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/03/2007. The National Provider Identifier (NPI) number assigned to this provider is 1265654875.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adam Gerstenblith, MD has received a total of $294,244 in payments from pharmaceutical and medical device companies, with $73.08 received in 2024. These payments were reported across 262 transactions from 8 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($208,276).
As a Medicare-enrolled provider, Gerstenblith has provided services to 17,013 Medicare beneficiaries, totaling 128,394 services with total Medicare billing of $14.4M. Data is available for 4 years (2020–2023), covering 70 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Retina Specialist, Retina Specialist
- Location Hagerstown, MD
- Active Since 05/03/2007
- Last Updated 12/06/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1265654875
Products in Payments
- EYLEA AFLIBERCEPT INJECTION (Biological) $113,540
- OZURDEX (Drug) $93,860
- EYLEA (Biological) $78,595
- EYLEA HD (Biological) $1,697
- VABYSMO (Drug) $150.00
- Vabysmo (Drug) $48.32
- XIPERE (Drug) $35.46
- Syfovre (Drug) $31.85
- Lucentis (Biological) $16.56
- SUSVIMO (Drug) $15.55
- BEOVU (Drug) $13.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Hagerstown
Christopher Vaccari, M.d, M.D
Internal Medicine — Payments: $58,882
Internal Medicine $58,882
Mary Howell, Md, MD
Internal Medicine — Payments: $35,983
Internal Medicine $35,983
Michael Mccormack, M.d, M.D
Internal Medicine — Payments: $23,820
Internal Medicine $23,820
Imtiaz Khurshid, Md, MD
Internal Medicine — Payments: $7,597
Internal Medicine $7,597
Dr. Syed Mahmood, M.d, M.D
Internal Medicine — Payments: $4,713
Internal Medicine $4,713
Dr. Muhammad Waseem, Md, MD
Internal Medicine — Payments: $3,874
Internal Medicine $3,874